Skip to main content
SpringerLink
Log in

Extraintestinal Manifestations of Inflammatory Bowel Disease

  • Chapter
Inflammatory Bowel Disease and Familial Adenomatous Polyposis

  • 790 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Das KM (1999) Relationship of extraintestinal involvements in inflammatory bowel disease. Dig Dis Sci 44(1):1–13

    Article  PubMed  CAS  Google Scholar 

  2. Bernstein CN, Blanchard JF, Rawsthorne P et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96(4):1116–1122

    Article  PubMed  CAS  Google Scholar 

  3. Snook JA, de Silva HJ, Jewell DP (1989) The association of autoimmune disorders with inflammatory bowel disease. Quart J Med 269:835–840

    Google Scholar 

  4. Brandtzaeg P, Halstensen TS, Kett K (1992) Immunopathology of inflammatory bowel disease. In: MacDermott RP, Stenson WF (eds) Inflammatory bowel disease, current topics in gastroenterology. Elsevier, London, pp 95–136

    Google Scholar 

  5. Padolsky DK (1991) Inflammatory bowel disease: Part 1. N Engl J Med 325:928–937

    Article  Google Scholar 

  6. Sartor RB (1995) Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis and experimental intestinal inflammation. Inflammatory bowel disease. In: Kirsner JB, Shorter RJ (eds) Lea & Febiger, Philadelphia, pp 96–124

    Google Scholar 

  7. MacDermott RP, Elson CO (1991) Mucosal immunology I. Gastroenterol Clin North Am 20:397–627

    Google Scholar 

  8. Breban M, Hammer RE, Richardson JA et al (1993) Transfer of the inflammatory disease of HLA B27 transgenic rats by bone marrow engraftment. J Exp Med 178:1607–1616

    Article  PubMed  CAS  Google Scholar 

  9. Taurog JD, Richardson JA, Croft JT et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364

    Article  PubMed  CAS  Google Scholar 

  10. Mizoguchi A, Mizoguchi E, Chiba C et al (1996) Cytokine imbalance and autoantibody production in T cell receptor-a mutant mice with inflammatory bowel disease. J Exp Med 183:847–856

    Article  PubMed  CAS  Google Scholar 

  11. Chapman RW, Cottone M, Selby WS et al (1986) Serum autoantibodies in ulcerative colitis and primary sclerosing cholangitis. Gut 27:86–91

    PubMed  CAS  Google Scholar 

  12. Tan EM (1991) Autoantibodies in pathology and cell biology. Cell 67:841–842

    Article  PubMed  CAS  Google Scholar 

  13. Satsagi J, Grootscholten C, Holt H et al (1996) Clinical pattern of familial inflammatory bowel disease. Gut 38:738–741

    Google Scholar 

  14. Rump JA, Scholmerich J, Gross V et al (1990) A new type of perinuclear anti-neutrophil cytoplasmatic antibody (p-ANCA) in ulcerative colitis but not in Crohn’s disease. Immunobiology 181:406–413

    PubMed  CAS  Google Scholar 

  15. Hoffenberg J, Fidanza S, Sauaia A (1999) Serologic testing for inflammatory bowel disease. J Pediatr 134:447–452

    Article  PubMed  CAS  Google Scholar 

  16. Lawrance IC, Murray K, Hall A et al (2004) A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 99:2186–2194

    Article  PubMed  Google Scholar 

  17. Satsagi J, Grootscholten C, Holt H et al (1996) Clinical pattern of familial inflammatory bowel disease. Gut 38:738–741

    Google Scholar 

  18. Seibold F, Slametschka D, Gregor M et al (1992) Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 107:532–536

    Google Scholar 

  19. Greenstein AJ, Janovitz HD, Sachar DB (1976) The extraintestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine 5:401–412

    Google Scholar 

  20. Reinshagen M, Von Tirpitz C (2003) Osteoporosis and other extraintestinal symptoms and complications of inflammatory bowel diseases. Dig Dis 21:138–145

    Article  PubMed  Google Scholar 

  21. Orchard TR (2001) Arthritis associated with inflammatory bowel disease. In: Bayless TM, Hanauer SB (eds) Advanced therapy of inflammatory bowel disease. Decker, Hamilton, London, pp 279–288

    Google Scholar 

  22. Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387–391

    Article  PubMed  CAS  Google Scholar 

  23. Punzi L, Podswiadek M, D’Incà R et al (2003) Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease. Ann Rheum Dis 62(12):1224–1226

    Article  PubMed  CAS  Google Scholar 

  24. De Vos M, De Keyser F, Mielants H et al (1998) Review article: bone and joint disease in inflammatory bowel disease. Aliment Pharmacol Ther 12:397–404

    Article  PubMed  Google Scholar 

  25. Podswiadek M, Punzi L, Stramare R et al (2004) The prevalence of radiographic sacroiliitis in patients affected by inflammatory bowel disease with inflammatory low back pain. Reumatismo 56(2):110–113

    PubMed  CAS  Google Scholar 

  26. De Vos M (2004) Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 20[Suppl 4]:36–42

    Article  PubMed  Google Scholar 

  27. Adler G, Reinshagen M (2003) Extraintestinale Manifestationen. Z Gastroenterol 41:54–61

    Article  PubMed  CAS  Google Scholar 

  28. Sieper J, Braun J (2001) New treatment options in ankylosing spondylitis: a role for anti-TNFa therapy. Ann Rheum Dis 60(Suppl 3):58–61

    Google Scholar 

  29. Compston JE (1995) Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmachol Ther 9:237–250

    Article  CAS  Google Scholar 

  30. Bernstein CN, Leslie WD (2004) Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 19:941–952

    Article  PubMed  CAS  Google Scholar 

  31. Schulte C, Dignass AU, Mann K et al (1998) Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4(4):268–275

    Article  PubMed  CAS  Google Scholar 

  32. Jahnsen J, Falch JA, Aadland E et al (1997) Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 40:313–319

    PubMed  CAS  Google Scholar 

  33. Dinca M, Fries W, Luisetto G et al (1999) Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 94(5):1292–1297

    Article  PubMed  CAS  Google Scholar 

  34. de Jong DJ, Corstens FH, Mannaerts L et al (2002) Corticosteroid-induced osteoporosis: does it occur in patients with Crohn’s disease? Am J Gastroenterol 97(8):2011–2015

    Article  PubMed  Google Scholar 

  35. Dear KL, Compston JE, Hunter JO (2001) Treatments for Crohn’s disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin Nutr 20(6):541–546

    Article  PubMed  CAS  Google Scholar 

  36. Bernstein CN, Blanchard JF, Metge C (2003) The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 98(8):1797–1801

    Article  PubMed  Google Scholar 

  37. Greenberg G, Feagan B, Martin F et al (1994) Oral budesonide for the treatment of active Crohn’s disease. N Engl J Med 331:836–841

    Article  PubMed  CAS  Google Scholar 

  38. Manolagas SC, Jilka RL (1995) Bone marrow, cytokine and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(5):305–311

    Article  PubMed  CAS  Google Scholar 

  39. Andreassen H, Rungby J, Dahlerup F et al (1997) Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 32:1247–1255

    Article  PubMed  CAS  Google Scholar 

  40. Lichtenstein GR (2003) Evaluation of bone mineral density in inflammatory bowel disease: current safety focus. Am J Gastroenterol 98(12):S24–S30

    Article  PubMed  Google Scholar 

  41. Sambrook P, Birmingham J, Kelly P et al (1993) Prevention of corticosteroids osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747–1752

    Article  PubMed  CAS  Google Scholar 

  42. Bernstein CN, Seeger LL, Anton PA et al (1996) A randomized placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroids-using patients with IBD: a pilot study. Aliment Pharmacol Ther 10:777–786

    Article  PubMed  CAS  Google Scholar 

  43. Cranney A, Welch V, Adachi JD et al (2001) Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev (4):CD003376

    Google Scholar 

  44. Nousari HC, Provost TT, Anhalt GJ (2001) Cutaneous manifestations of inflammatory bowel disease. In: Bayless TM, Hanauer SB (eds) Advanced therapy of inflammatory bowel disease. B.C. Becker, Hamilton, pp 271–274

    Google Scholar 

  45. Tromm A, May D, Almus E et al (2001) Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 39:137–144

    Article  PubMed  CAS  Google Scholar 

  46. Fleisher M, Rubin S, Levine A et al (2002) Infliximab in the treatment of refractory erythema nodosum of IBD. Gastroenterology 122(Suppl 1):A618

    Google Scholar 

  47. Bennet ML, Jackson JM, Jorizzo JL et al (2000) Pyoderma Gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 79:37–46

    Article  Google Scholar 

  48. Wollina V (2002) Clinical management of pyoderma gangrenosum. Am J Clinical Dermatol 3:14–58

    Google Scholar 

  49. Hohenleutner U, Mohr VD, Michel S et al (1997) Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum. Lancet 350:1748

    Article  PubMed  CAS  Google Scholar 

  50. D’Incà R, Fagiuoli S, Sturniolo GC (1998) Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Intern Med 128:783–784

    PubMed  Google Scholar 

  51. Regueiro M, Valentine J, Plevy S et al (2003) Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98:1824–1826

    Article  Google Scholar 

  52. Brooklyn TN, Dunnill GS, Shetty A et al (2005) Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind placebo controlled trial. Gut (Epub PMID:16188920)

    Google Scholar 

  53. Tavarela Veloso F (2004) Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 20(Suppl 4):50–53

    Article  Google Scholar 

  54. Fujimoto E, Fujimoto N, Kuroda K et al (2004) Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 151:1090–1092

    Article  PubMed  CAS  Google Scholar 

  55. Soukiasian S, Foster CS, Raizman MB (1994) Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 118:601–611

    PubMed  CAS  Google Scholar 

  56. Lamers CBHW (1997) Treatment of extraintestinal complication of ulcerative colitis. Eur J Gastroenterol Hepatol 9:850–853

    PubMed  CAS  Google Scholar 

  57. Bargiggia S, Maconi G, Elli M et al (2003) Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clinical Gastroenterol 36(5):417–420

    Article  Google Scholar 

  58. Hutchinson R, Tyrrel PN, Kumar D et al (1994) Pathogenesis of gallstones in Crohn’s disease: an alternative explanation. Gut 35(1):94–97

    PubMed  CAS  Google Scholar 

  59. Wiesner RH (1994) Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 69:969–982

    PubMed  CAS  Google Scholar 

  60. Spurkland A, Saarinen S, Boberg KM et al (1999) HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 53:459–69

    Article  PubMed  CAS  Google Scholar 

  61. Grant AJ, Lalor PF, Salmi M et al (2002) Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359:150–157

    Article  PubMed  Google Scholar 

  62. Spirli C, Fabris L, Duner E et al (2003) Cytokine-stimulated nitric oxide production inhibits adenyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124:737–753

    Article  PubMed  CAS  Google Scholar 

  63. Cullen SN, Chapman RW (2005) Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 21:933–948

    Article  PubMed  CAS  Google Scholar 

  64. Beuers U, Spengler U, Kruis W et al (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepathology 16:707–714

    CAS  Google Scholar 

  65. Stiehl A, Walker S, Sthiel L et al (1994) Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20:57–64

    Article  PubMed  CAS  Google Scholar 

  66. Mitchell SA, Bansi DS, Hunt N et al (2001) A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121:900–907

    Article  PubMed  CAS  Google Scholar 

  67. Buurgert SL, Brown BP, Kirkpatrick RB (1984) Positive corticosteroid response in early primary sclerosing cholangitis (abstract). Gastroenterology 86:1037(A)

    Google Scholar 

  68. Lindor KD, Wiesner RH, Colwell LJ et al (1991) The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 86:57–61

    PubMed  CAS  Google Scholar 

  69. Knox TA, Kaplan MM (1991) Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 86:546–552

    PubMed  CAS  Google Scholar 

  70. Knox TA, Kaplan MM (1994) A double-blind controlled trial of oral pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 106:494–499

    PubMed  CAS  Google Scholar 

  71. Lindor KD, Jorgensen RA, Anderson ML et al (1996) Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 91:511–515

    PubMed  CAS  Google Scholar 

  72. Talwalkar JA, Lindor KD (2005) Primary sclerosing cholangitis. Inflamm Bowel Disease 11(1):62–72

    Article  Google Scholar 

  73. Bharucha AE, Jorgensen R, Lichtman SN et al (2000) A pilot study of pentoxifylline for the treatment primary sclerosing cholangitis. Am J Gatroenterol 95:2338–2342

    Article  CAS  Google Scholar 

  74. Epstein MP, Kaplan MM (2004) A pilot study of etanercept in the treatment primary sclerosing cholangitis. Dig Dis Sci 49:1–4

    Article  PubMed  CAS  Google Scholar 

  75. Moayyeri A, Daryani NE, Barhami H et al (2005) Clinical course of ulcerative colitis in patients with or without primary sclerosing cholangitis. J Hepatol Gastroenterol 20:366–370

    Article  Google Scholar 

  76. Gorgun E, Remzi FH, Manilich E et al (2005) Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case control study. Surgery 138(4):631–637

    Article  PubMed  Google Scholar 

  77. Chambers WM, Warren BF, Jewell DP et al (2005) Cancer surveillance in ulcerative colitis. Br J Surg 92(8):928–936

    Article  PubMed  CAS  Google Scholar 

  78. Broome U, Lindberg G, Lofberg R (1992) Primary sclerosing-cholangitis in ulcerative colitis: a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 102(6):1877–1880

    PubMed  CAS  Google Scholar 

  79. Pardi DS, Loftus EV, Kremers WK et al (2003) Ursodeoxycholic acid acts as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889–893

    Article  PubMed  CAS  Google Scholar 

  80. Wolf JM, Rybicki LA, Lashner BA (2005) The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 22:783–788

    Article  PubMed  CAS  Google Scholar 

  81. Haagsma EB, Van Den Berg AP, Kleinbeuker JH et al (2003) Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 18(1):33–44

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University of Padua, Padua, Italy

    Giacomo C. Sturniolo, Michela Barollo & Renata D’Incà

Authors
  1. Giacomo C. Sturniolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michela Barollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renata D’Incà
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery and Gastroenterology, University of Verona, Verona, Italy

    Gian Gaetano Delaini

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Sturniolo, G.C., Barollo, M., D’Incà, R. (2006). Extraintestinal Manifestations of Inflammatory Bowel Disease. In: Delaini, G.G. (eds) Inflammatory Bowel Disease and Familial Adenomatous Polyposis. Springer, Milano. https://doi.org/10.1007/88-470-0434-9_7

Download citation

  • DOI: https://doi.org/10.1007/88-470-0434-9_7

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0433-7

  • Online ISBN: 978-88-470-0434-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation